Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AgomAb Therapeutics
Biotech
Agomab uses $100M series C to push Crohn's drug through phase 2
A week after entering its lead asset into a phase 2 trial, Agomab has secured $100 million in series C financing to power up its pipeline.
James Waldron
Oct 11, 2023 8:50am
Fierce Biotech's 2022 Fierce 15
Sep 12, 2022 3:00am
Pfizer jumps into bed with Agomab, leading series B extension
Jul 13, 2022 10:10am
CRISPR cans R&D chief in SEC filing—Chutes & Ladders
Dec 22, 2021 9:30am
AgomAb raises $74M to develop regenerative pathway modulators
Mar 10, 2021 5:00am